Please assess the completion status of the following clinical trial:

Trial Title: Protective Effect of Mangafodipir Against Oxaliplatin Neurotoxicity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* NCI CTC grade 2 or more neuropathy induced by oxaliplatine~* At least 18 years old~* ECOG PS: 2 or less~* Life expectancy longer than 3 months~* Written informed consent~* Adequate hematologic, liver and renal functions~Exclusion Criteria:~* Known hypersensibility to oxaliplatine~* Cancer resistant to oxaliplatine~* Fertile woman or man not willing to use adequate contraception~* Pregnant or lactating women~* Vitamin B6 administration within 48h prior to mangafodipir administration~* Uncontrolled infection~* Treatment with any other investigational agent, or participation in another clinical trial within 3 weeks prior to first administration of mangafodipir~* Evidence of any other disease or condition that contra-indicates the use of an investigational drug~* No Social Security insurance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).